Harry J. F. Bloomfield, QC., M.B.A.
Chaiman & Director
Harry J. F. Bloomfield, QC., M.B.A., is a lawyer, business manager and philanthropist. Born in Montreal, Quebec, he received a Bachelor of Arts degree from McGill University in 1965, a Bachelor of Civil Law degree from Université de Montréal in 1968, and joined the Bar of Quebec in 1969. Bloomfield received a Master of Business Administration from the Harvard Graduate School of Business Administration in 1971. He was appointed Queen's Counsel in 1991. Bloomfield has served on numerous boards, public and private, including Heller Financial Canada (now part of GE Capital); Banco Comercial Português, the Canadian subsidiary of Sottomayor Bank of Portugal; British Controlled Oilfields, Genoil Inc., Balkan Resources Inc., and Wi2Wi Inc. In May 2011, he was elected to the Board of Directors of Miraculins Inc. (TSX-V:MOM), a medical diagnostic company, and in April 2012 he was elected the board’s Chairman.
Christopher J. Moreau
CEO and Director
Mr. Moreau is a seasoned business professional in the life sciences sector with a strong background in biotechnology research, business development and a deep expertise in the capital markets. Mr. Moreau was previously President & CEO and Director of a publicly traded company focussed on the research & development of screening tests for prostate cancer, skin cholesterol and type 2 diabetes. He has raised in excess of $30 million from the capital markets and has over 30 years of senior management experience in private & publicly traded company environments.
Raj Attariwala, MD, PhD.
Dr. Attariwala is a dual board certified Radiologist and Nuclear Medicine physician certified in both Canada and the United States. He received his formal medical training at University of British Columbia with periods of specialized medical training at Memorial Sloan Kettering Cancer Centre (New York), UCLA and USC. He holds a doctorate in Biomedical Engineering from Northwestern University (Evanston, IL).
Dr. Mark Williams, PhD.
Dr. Williams was a co–founder of the Algernon Pharmaceuticals drug repurposing program and was actively engaged as the Company’s Chief Scientific Officer until March 1st, 2021. He has over 15 years of experience in drug and medical device development and has authored multiple patents. He has specific expertise and skill sets in taking companies from the discovery process to Phase 2 trials including cGMP manufacturing and toxicology. He holds a PhD in Microbiology from the University of Alberta, and an MBA from the University of Manitoba.
David Levine has been in the life sciences and technology sectors for over twenty-five years. He started his career at Baxter Healthcare. Mr. Levine has extensive experience running drug and device manufacturing operations, commercializing life sciences innovation and has obtained regulatory approvals for drugs and devices on a global basis. He is active in health technology, pharmacy technology, and technology mergers and acquisitions.